Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Acquires Affinity BioReagents

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it has acquired privately held antibody maker Affinity BioReagents for an undisclosed amount.
 
Golden, Colo.-based Affinity makes monoclonal and polyclonal antibodies, peptides, proteins, and other reagents. The firm, which offers more than 35,000 reagents, also provides recombinant proteins and custom antibody-production services, said Thermo Fisher.
 
Affinity had around $6 million in revenues in 2007 and will be integrated into Thermo Fisher’s Analytical Technologies segment.
 
The deal follows Thermo Fisher’s acquisition a couple of weeks ago of Open Biosystems, a privately held provider of RNAi research products, for an undisclosed sum.
 

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.